Acknowledgements:
Author contribution statement: All authors met the criteria for
authorship
Financial statement: No financial support was received for the submitted
work
Conflict of Interest Statement
MM reports research grants from AstraZeneca, Sanofi, Methapharm
Specialty Pharamceuticals and Mirimus, consulting fees from AstraZeneca,
Sanofi, Respiplus, GSK, Mirimus. PN reports research grants from
AstraZeneca, Teva, Sanofi, Foresee and consulting fees from AstraZeneca,
Teva, Sanofi, Equillium, Arrowhead pharma. All other authors have no
conflict of interest within the scope of the submitted work.
Table 1: Patient characteristics of severe asthma patients with
normalized FeNO low versus raised FeNO after treatment with anti-IL5
biologic.